Rezdiffra (Resmetirom) Nutrition for Best Outcomes

What the FDA Approval Means for MASH Treatment

Resmetirom became the first drug approved specifically for MASH (formerly called NASH) when the FDA granted approval on March 14, 2024 [1]. The approval covered adults with noncirrhotic MASH and liver fibrosis stages F2 or F3, to be used alongside diet and exercise. That last phrase, "alongside diet and exercise," is not a formality. The MAESTRO-NASH trial explicitly required participants to follow dietary counseling throughout the 52-week study period [2].

What MASH Is and Why Nutrition Matters So Much

MASH is the inflammatory, fibrosis-producing form of metabolic dysfunction-associated steatotic liver disease (MASLD). The American Association for the Study of Liver Diseases (AASLD) 2023 guidance states: "Weight loss of at least 7 to 10% through lifestyle intervention remains the most validated approach for histologic improvement in MASH" [3]. Resmetirom does not replace that target. It adds a pharmacological mechanism on top of it.

The liver fat that resmetirom helps clear is, in large part, generated by dietary carbohydrates and saturated fats through de novo lipogenesis. Reducing those substrates while the drug is active gives the THR-beta receptor more room to work. A 2023 meta-analysis published in Hepatology covering 22 randomized controlled trials (N=2,809) confirmed that dietary interventions producing 7 to 10% weight loss improved MASH histology significantly more than <5% weight loss, with an odds ratio of 3.1 (95% CI 2.1 to 4.6, P<0.001) [4].

The Mechanism Behind the Nutrition-Drug Interaction

Resmetirom selectively activates THR-beta receptors in hepatocytes, which increases fatty acid oxidation and reduces lipogenic gene expression [5]. Dietary fructose directly upregulates those same lipogenic genes (FASN, ACC1) via ChREBP and SREBP-1c pathways. Eating high-fructose foods while taking resmetirom creates a biochemical headwind. The drug pushes against fat synthesis; a fructose-heavy diet pushes back.

Calorie Targets and Macronutrient Breakdown

A calorie deficit of 500 to 750 kcal per day is the threshold most used in MASH clinical trials and AASLD guidance [3]. For a 90 kg adult eating 2,400 kcal/day at baseline, that means targeting 1,650 to 1,900 kcal/day. Specific macronutrient ratios matter as much as total calories.

Carbohydrates: The Fructose Problem

Total carbohydrate intake should prioritize fiber-rich, low-glycemic sources. Added sugar, and fructose specifically, drives hepatic de novo lipogenesis more than any other macronutrient. A controlled feeding trial published in JAMA Network Open (N=41) showed that reducing added sugar from 25% to <10% of total energy intake for 9 weeks reduced liver fat by 22% on MRI-PDFF [6]. That reduction happened without weight loss, isolating fructose as a direct liver-fat driver independent of total calories.

Practical targets:

• Added sugar: <25 g/day (American Heart Association limit for women is 25 g/day, men 36 g/day) [7]
• Fructose from beverages: zero. Eliminate sugar-sweetened sodas, fruit juices, and energy drinks entirely.
• Fiber: 25 to 35 g/day from vegetables, legumes, and whole grains. Soluble fiber from oats and beans feeds gut microbiota that produce short-chain fatty acids, which reduce hepatic inflammation [8].

Fat: Quality Over Quantity

Total fat intake is less critical than fat type. Saturated fat from red meat and full-fat dairy directly activates inflammatory pathways in hepatic stellate cells, accelerating fibrosis [9]. Replacing saturated fat with monounsaturated fat (olive oil, avocado) or omega-3 polyunsaturated fat reduces hepatic triglyceride content.

A 12-week randomized trial in Journal of Hepatology (N=98) found that participants randomized to olive oil as the primary fat source had a 19% greater reduction in liver stiffness on transient elastography compared to those using sunflower oil (P<0.04) [10]. Extra-virgin olive oil is the practical recommendation.

Omega-3 fatty acids from fatty fish (salmon, mackerel, sardines) or supplements may provide additive benefit. The WELCOME trial (N=103) tested 4 g/day of purified EPA+DHA over 15 to 18 months and found a 4.2% absolute reduction in liver fat by MRI compared to placebo [11]. Two to three servings of fatty fish per week provides roughly 1.5 to 2 g of combined EPA+DHA without supplementation.

Protein: Enough to Preserve Muscle

MASH is often associated with sarcopenia. Weight loss from caloric restriction, if paired with inadequate protein, worsens muscle loss and can reduce resting metabolic rate, making weight maintenance harder long-term. The European Association for the Study of the Liver (EASL) recommends 1.2 to 1.5 g of protein per kilogram of body weight per day for patients with liver disease who do not have cirrhosis [12]. For a 90 kg patient, that is 108 to 135 g of protein daily.

Plant-based protein sources (legumes, tofu, tempeh) carry added benefit because they supply fiber and reduce the ammonia load on the liver. Lean animal proteins (chicken, turkey, fish, egg whites) are acceptable. Processed red meat should be limited to <2 servings per week based on its association with advanced MASH fibrosis in observational data [9].

The Mediterranean Diet Pattern for MASH

The Mediterranean dietary pattern consistently outperforms other named diets in MASH clinical studies. A 2022 systematic review in Nutrients (N=7 trials, 521 participants) found that Mediterranean diet adherence reduced liver fat by a mean of 3.1 percentage points on MRI-PDFF versus control diets (P<0.001) [13]. The pattern aligns with every macronutrient recommendation above.

Core Components

• Vegetables: 3 to 5 cups per day, emphasizing leafy greens, cruciferous vegetables, and tomatoes
• Fruit: 2 to 3 servings per day of whole fruit (not juice); berries are preferred for their lower glycemic index and high anthocyanin content
• Whole grains: Oats, barley, farro, quinoa instead of white rice or white bread
• Legumes: Lentils, chickpeas, black beans at least 4 times per week
• Fish and seafood: 2 to 3 times per week
• Olive oil: Primary cooking and dressing fat, 2 to 4 tablespoons daily
• Nuts and seeds: A 30 g handful of walnuts or almonds daily
• Dairy: Low-fat or fermented options (Greek yogurt, kefir) in moderate amounts
• Red meat: <2 times per week
• Sweets and processed foods: Rare, not weekly

A Realistic Daily Meal Structure

Breakfast: Greek yogurt with berries and rolled oats. No fruit juice.

Lunch: Large mixed salad with chickpeas, olive oil and lemon dressing, plus a piece of whole-grain bread.

Dinner: Baked salmon with roasted vegetables (broccoli, zucchini, bell pepper) dressed in olive oil. A small portion of farro or lentils.

Snacks: A handful of walnuts, raw vegetables with hummus, or a piece of whole fruit.

This structure keeps added sugar well under 25 g/day, delivers >30 g of fiber, and provides adequate protein without relying on saturated fat sources.

Alcohol: A Clear Limit

The FDA prescribing information for Rezdiffra does not specify an alcohol limit, but the underlying biology makes the answer straightforward. Even moderate alcohol intake accelerates hepatic fibrosis in MASH through oxidative stress, CYP2E1 activation, and direct hepatocyte lipotoxicity [14]. The AASLD MASH guidance states: "Alcohol abstinence is recommended for all patients with MASH" [3].

Zero is the evidence-based target. Patients who find complete abstinence difficult should discuss a structured reduction plan with their hepatologist before their next dose. One alcohol-free month produces measurable improvements in liver enzymes and liver stiffness in people with metabolic liver disease [15].

Managing GI Side Effects Through Diet

In MAESTRO-NASH, 32% of participants on resmetirom 100 mg reported diarrhea and 26% reported nausea as adverse events [2]. Both are dose-dependent and most common in the first 4 to 8 weeks. Dietary adjustments reduce both.

Reducing Nausea

• Take the tablet with a meal, not on an empty stomach. The FDA label specifies "with food" for this reason.
• Start with smaller, more frequent meals (4 to 5 per day) rather than three large meals during the first 4 weeks.
• Avoid high-fat meals at the time of dosing. The pharmacokinetic data from the MAESTRO-NASH protocol showed that a high-fat meal increased resmetirom Cmax by approximately 36% versus a low-fat meal [2]. Higher peak concentrations correlate with GI side effects.
• Ginger tea or ginger chews (250 to 500 mg crystallized ginger) have evidence for chemotherapy-induced nausea and may help mild drug-related nausea [16].

Reducing Diarrhea

• Temporarily reduce insoluble fiber (raw cruciferous vegetables, wheat bran) during the first 2 weeks, then reintroduce gradually.
• Increase soluble fiber (oats, psyllium husk, cooked vegetables) to slow gastric transit.
• Stay hydrated. Aim for 2 to 2.5 liters of water daily.
• Probiotic-rich foods (kefir, yogurt with live cultures) may modestly reduce antibiotic-associated and drug-induced diarrhea duration based on a 2020 Cochrane review covering 82 trials [17].

If diarrhea or nausea persists beyond 8 weeks at full dose, contact the prescribing physician. Dose reduction from 100 mg to 80 mg is a documented management option in the prescribing information [1].

Physical Activity: The Dietary Co-Factor

Nutrition and exercise are inseparable in MASH management. The reason to cover both here is that physical activity directly affects how efficiently resmetirom can reduce liver fat, through a shared mechanism: AMP-activated protein kinase (AMPK) activation. Exercise activates AMPK in hepatocytes, which suppresses the same lipogenic pathways that resmetirom targets via THR-beta [18].

A 2022 meta-analysis in Gut covering 21 trials (N=1,530) found that 150 to 240 minutes per week of moderate-intensity aerobic exercise reduced liver fat by a mean of 3.7 percentage points on MRI-PDFF, independent of weight loss [18]. Walking briskly for 30 to 35 minutes on 5 days per week meets that target.

Resistance training adds muscle mass, which increases insulin sensitivity and reduces the hyperinsulinemia that drives hepatic de novo lipogenesis. The combination of aerobic and resistance training produced greater liver fat reduction than either alone in a 16-week RCT published in Hepatology (N=220, P<0.001) [19].

Food and Drug Interactions to Know

CYP3A4 and OATP1B Considerations

Resmetirom is a substrate of CYP3A4 and OATP1B1/1B3 transporters. Grapefruit and grapefruit juice contain furanocoumarins that inhibit CYP3A4 in the intestinal wall. The FDA label recommends avoiding grapefruit juice while taking resmetirom because it may increase plasma concentrations unpredictably [1]. Seville oranges (often in marmalades) carry the same risk. Regular navel oranges are fine.

Timing and Meal Composition

Take resmetirom at approximately the same time each day with a low-to-moderate fat meal. "Low-to-moderate fat" means the meal contains 10 to 25 g of total fat. A bowl of oatmeal with berries and a side of eggs fits this window. A bacon-and-cheese breakfast sandwich does not.

Vitamin D and Micronutrients

MASH is associated with vitamin D deficiency in 55 to 75% of patients, based on cross-sectional data from the NASH Clinical Research Network [20]. Vitamin D insufficiency reduces hepatic anti-inflammatory signaling. A serum 25-OH vitamin D level should be checked at the first follow-up visit after starting resmetirom. If below 30 ng/mL, supplementation of 2,000 to 4,000 IU/day of vitamin D3 is appropriate per Endocrine Society guidelines [21].

Choline is another micronutrient frequently low in patients with MASH. Choline deficiency in animals reliably induces steatohepatitis [22]. Eggs (1 large egg provides 147 mg choline), salmon, chicken breast, and legumes are practical dietary sources.

Monitoring Progress: What to Track at Home

Patients taking resmetirom should track four things between clinic visits to assess whether the nutrition plan is working alongside the drug:

Body weight. Weekly morning weight on the same scale, before eating. A downward trend of 0.5 to 1 lb/week confirms a caloric deficit. The MAESTRO-NASH trial showed that participants who achieved >3% weight loss by week 12 had significantly higher rates of MASH resolution at week 52 [2].

Waist circumference. Measured monthly at the iliac crest level. Reductions in waist circumference correlate with visceral fat loss, which is the fat depot most closely linked to hepatic inflammation.

Dietary sugar log. A 3-day food record using a free app (Cronometer or MyFitnessPal) every 6 to 8 weeks takes 15 minutes and quantifies added sugar and fiber intake against the targets above.

GI symptom diary. Noting the time of dosing, meal composition, and GI symptoms for the first 8 weeks allows patients and clinicians to identify which foods trigger nausea or diarrhea and adjust accordingly.

At the 12-week clinic visit, liver enzymes (ALT, AST, GGT) and lipid panel should be reviewed. In MAESTRO-NASH, resmetirom 100 mg reduced LDL-C by a mean of 13.6 mg/dL and triglycerides by 22.5 mg/dL at 52 weeks [2]. If lipid markers are not improving, the dietary plan warrants reassessment before dose changes are considered.

What Patients Report About Daily Life on Rezdiffra

Patient-reported outcomes from the MAESTRO-NASH trial used the NASH-CHECK questionnaire. Participants in the resmetirom arms reported significant improvements in fatigue and right-upper-quadrant discomfort scores compared to placebo at 52 weeks (P<0.05) [2]. Both symptoms are tied to liver inflammation, and both improve faster when the dietary substrate driving that inflammation is reduced.

Practically, the first 4 weeks are the hardest. Nausea and loose stools are most frequent in weeks 1 to 4. Patients who prepare by switching to smaller, lower-fat meals before their first dose report fewer interruptions to daily activity. After week 8, the large majority of patients in MAESTRO-NASH tolerated the full 100 mg dose without active GI complaints [2].

The once-daily dosing schedule fits most routines. Taking the tablet with breakfast works for most patients because breakfast tends to be a naturally lower-fat meal and the morning habit is easy to anchor.